NeuroOne Medical Technologies Corporation has reported accelerating commercial momentum with record procedure volume for its OneRF® brain ablation system in the first quarter of fiscal 2026 and announced early clinical success in treating trigeminal neuralgia, one of medicine's most severe pain conditions. The company is strategically advancing its platform technology across three new market opportunities—drug delivery, basivertebral nerve ablation (BVNA), and spinal cord stimulation—each representing a potential U.S. addressable market exceeding $1 billion annually, with key milestones expected throughout 2026.
The importance of this development lies in NeuroOne's demonstrated ability to translate its FDA-cleared electrode technology into multiple therapeutic applications for neurological disorders, potentially transforming treatment paradigms for conditions ranging from epilepsy to chronic pain. The company's commercial progress validates its platform approach, where a single core technology can be adapted for diverse clinical needs, creating significant efficiency in development and potential for market disruption.
NeuroOne's brain ablation program, commercialized through an exclusive distribution partnership with Zimmer Biomet, delivered its strongest quarter since launch, with nearly 50% of all ablations performed since 2024 occurring in Q1 fiscal 2026 alone. This growing adoption is significant because it demonstrates real-world physician acceptance of the technology for treating neurological conditions. Under the distribution agreement, Zimmer Biomet covers all marketing and sales costs, meaning incremental procedures directly benefit NeuroOne's margin structure.
Following FDA 510(k) clearance last August, NeuroOne has completed nine trigeminal neuralgia cases across three centers, with all patients reportedly pain-free. This condition affects approximately 150,000 new patients annually in the United States and represents one of medicine's most debilitating pain conditions. The company is currently evaluating both direct commercialization and strategic licensing partnerships for this application, with a limited market release expected by the end of Q2 fiscal 2026.
The company's expansion into larger market opportunities is particularly noteworthy given recent industry validation. Boston Scientific acquired Relievant Medsystems, developer of the Intracept® basivertebral nerve ablation system, in late 2023 for approximately $850 million upfront plus additional contingent payments, representing roughly a 12× multiple of expected revenue at the time. The therapy has since become one of the fastest-growing products in Boston Scientific's pain management portfolio. NeuroOne believes its platform advantages can be applied to compete effectively in the BVNA market while pursuing similar opportunities in drug delivery and spinal cord stimulation.
NeuroOne's drug delivery system is now six months ahead of its original development schedule, targeting commercial readiness for investigational clinical or animal studies by the end of Q3 fiscal 2026. The company is initially focused on glioblastoma, an aggressive brain cancer with median survival measured in months, as well as gene and cell-based therapies. This exemplifies the platform's versatility—the same foundational electrode technology adapted to address entirely new clinical challenges.
For its basivertebral nerve ablation program, NeuroOne is pursuing a capital-efficient strategy by leveraging its existing OneRF® generator, temperature probe, and ablation electrode while outsourcing access tools. The company believes its multi-contact sEEG probes offer doctors greater flexibility during device placement, representing a potential competitive advantage. Multiple advisory board meetings with leading pain specialists have confirmed the clinical rationale and design principles for this chronic low back pain treatment.
The spinal cord stimulation percutaneous paddle lead program has initiated a six-month animal study in preparation for first-in-human trials. This technology utilizes a percutaneously-placed thin-film paddle electrode to deliver precise electrical stimulation to block pain signals, potentially opening paddle electrode implantation to both pain management doctors and neurosurgeons. Currently, surgeons predominantly place paddle electrodes through invasive procedures.
Financially, NeuroOne guides to at least $10.5 million in product revenue for fiscal year 2026, a minimum 17% increase over fiscal year 2025. This guidance excludes potential contributions from the recently cleared trigeminal nerve ablation system. The company maintains a strong balance sheet with zero debt, $3.6 million in cash and cash equivalents, and $6.8 million in working capital as of December 31, 2025.
NeuroOne's growing intellectual property portfolio now includes 13 U.S. patents issued or pending plus four internationally, supporting its platform technology across multiple applications. The company's commercial infrastructure through Zimmer Biomet provides national reach without corresponding SG&A burden, while active discussions with potential partners could generate non-dilutive cash in 2026. These developments position NeuroOne for several strategic and commercial inflection points beginning this year across its expanding pipeline of neurological treatments.
